Enter the Chimera
Cancer is undoubtedly one of the most dreaded maladies known to humans. It is defined as a condition where cells proliferate uncontrollably . Besides surgery, conventional cancer treatments include radiotherapy and chemotherapy that aim at selectively killing cancer cells. However, this is often accompanied by unwanted side effects, as these therapies tend to kill off healthy cells as well . Fortunately, recent developments of immunotherapies allow us to fight cancer in a more precise manner, with our own immune system. Enter the Chimera – the renowned chimeric antigen receptor T cell (CAR-T cell) therapy, a man-made hybrid created for the sole purpose of eradicating cancer. The idea of this therapy is to extract a type of immune cell known as T cells from the patient, genetically engineer them into CAR-T cells in vitro, and infuse the transformed cells back into the patient’s body. With the newly gained ability to recognise and attack cancer cells, CAR-T cells are almost like a "living drug" against cancer, fighting them off cell by cell!
Fact Number 1: The T Cell Involved is Known as Cytotoxic T Cell
Also known as killer T cells, one can infer from its name that this cell type kills other cells ("cyto-" meaning cell and "toxic" implying lethality). Cytotoxic T cells usually kill cells that are damaged, as their continued existence is undesirable for the body, such as virus-infected cells which are hijacked to shelter and replicate the pathogen. The major task of the T cell is to distinguish damaged cells from healthy cells, kill the former and spare the latter. The identification is enabled by a T-cell receptor (TCR), which recognises an antigen presented on the surface of damaged cells but not healthy cells. When bound to an antigen, the TCR sends signals to activate the T cell so that it will be triggered to kill the damaged cell by inducing cell lysis1.
Fact Number 2: Antibodies are Produced by Another Class of Immune Cells Called B cells
Plasma cells, which are differentiated from B cells, produce proteins called antibodies. Shaped like a "Y", antibodies have the trademark function of being able to bind specifically to its corresponding antigen using the two tips of the "Y". Known as variable regions, the pairs of tips vary vastly among different antibodies, defining the target of an antibody and conferring an "identity" on it. On the contrary, the remaining part is known as the constant region; the same constant regions may be shared by different antibodies.
Upon being bound by antibodies, the antigen itself (sometimes toxins) or the unwanted entities with the antigen on surface (such as cancer cells or pathogens) will be recognised by other immune cells, which may swallow them whole in a process called phagocytosis. However, this system is not perfect. In the case of cancer cells, they are not always recognised as the enemies within our bodies.
Figure 1. Structure of an antibody.
The Powerful Chimera – CAR-T Cells
In fact, the CAR-T cell derives its name from the Chimera, a fire-breathing hybrid creature merged from a lion, a goat and a snake, in Greek mythology. The CAR-T cell is literally the merged form of cytotoxic T cells and antibodies. It utilises a chimeric TCR to identify cancer cells. The word "chimeric" describes the fusion of several protein domains (parts of proteins) sourced from different proteins, that have distinct functions.
Like all receptors, the CAR2 has three domains: an extracellular domain (outside the cell), a transmembrane domain (embedded in the plasma membrane) and an intracellular domain (inside the cell) . In this case, the extracellular domain of the CAR is derived from the antigen-binding variable region of the antibody which specifically binds to tumor-associated antigens. Tumor-associated antigens tend to be more abundant on cancer cells, though they are not necessarily exclusive to them. It is hoped that the chosen extracellular domain can direct CAR-T cells to cancer cells. Then, there is the transmembrane domain, which is usually sourced from existing receptors. This structural domain serves to anchor the entire CAR onto the cell membrane. Lastly, there is the intracellular domain which contains the intracellular signaling domains of a regular TCR along with that of other co-stimulatory receptors. In simpler words, it can also activate the CAR-T cell when the extracellular domain binds to the tumor-associated antigen, enabling the lysis of cancer cells.
Figure 2. Structure of a chimeric antigen receptor (CAR).
"Assembling" Our Weapon from Scratch
So, how do we actually create CAR-T cells? Once the desired protein domains have been chosen, we will fuse their respective DNA sequences together and integrate them into the genome of a T cell sourced from the patient’s own body by some genetic engineering techniques in a lab. This brings CAR-T cells into existence because the cells will now be able to produce the customised weapon (the said chimeric receptor) with our lines of commands (the DNA sequences). The CAR-T cells are re-delivered back into the patients’ body afterwards as a "iving drug".
Efficacy and Challenges
Given its potential to cure cancer, CAR-T cells have undergone many clinical trials to test its effectiveness for various types of cancer. According to a study from the University of Chicago , the success rate of CAR-T cell therapy is currently at 30 to 40% for long-term remission of some cancers.
While potent, there are certainly many challenges in perfecting CAR-T cell therapy. One problem is on-target off-tumor toxicity. As mentioned, tumor-associated antigens are not exclusive to cancer cells and may be present on the surface of healthy cells. This sometimes leads to a safety issue, when CAR-T cell targets the antigen on a healthy cell by mistake. Other challenges presented lie in the tumor microenvironment (TME), where the cancer cells reside, that may suppress the function of CAR-T cells . Even now, scientists are working hard to improve upon these weaknesses, with more advanced versions of CAR-T cells popping up frequently. Some of the notable improvements include adding logic gates3 to CAR-T cells to increase specificity and safety , while some aim to counter the immunosuppressive TME with supplementary molecules such as immune checkpoint inhibitors, to avoid the cancer cells from circumventing the assault of CAR-T cells by "cheating" .
Owing to its reputation as the programmed cancer killer, CAR-T cells have garnered much attention in recent years. Where humans have traditionally relied on chemical drugs, CAR-T cells represent a new class of "living" drugs. Immunotherapy, which includes CAR-T cells, is set apart from other therapies because such treatments utilise our own immune system to fight against diseases. In truth, the immune system has always been a faithful guardian, defending our body from diseases all the time, sometimes even without us noticing; it is only fitting that, with the help of an innovative upgrade, it can be used to dispatch rebellious cells that turn cancerous. Hopefully, this will prove to be a more effective therapy, with substantially less side effects, bringing humans one step closer to curing cancer effectively!
1 T cells can effectively kill the target cell by releasing proteins that poke holes on its plasma membrane, causing a cell to burst, known as cell lysis. 2 For the chimeric one, it is more often referred to as chimeric antigen receptor (CAR) instead of chimeric T-cell receptor. However, they refer to the same thing but just named from different perspectives – a receptor on T cells versus a receptor which binds to antigen. 3 Logic gates perform logical operations and produces outputs according to inputs it receives.
 Shiel, W. C. Jr. (n.d.). Medical Definition of Cancer. Retrieved from https://www.medicinenet.com/script/main/art.asp?articlekey=2580  Cancer Research UK. (2020, June 10). How chemotherapy works. Retrieved from https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/chemotherapy/how-chemotherapy-works  Ghorashian, S., Pule, M., & Amrolia, P. (2015). CD19 chimeric antigen receptor T cell therapy for haematological malignancies. British Journal of Haematology, 169(4), 463–478. doi: 10.1111/bjh.13340  Bartosch, J. (2019, October 17). Three years after CAR T-cell therapy for lymphoma, patient still cancer-free. Retrieved from https://www.uchicagomedicine.org/forefront/cancer-articles/a-walking-miracle-car-t-cell-therapy  Tormoen, G. W., Crittenden, M. R., & Gough, M. J. (2018). Role of the immunosuppressive microenvironment in immunotherapy. Advances in Radiation Oncology, 3(4), 520–526. doi: 10.1016/j.adro.2018.08.018  Morsut, L., Roybal, K. T., Xiong, X., Gordley, R. M., Coyle, S. M., Thomson, M., & Lim, W. A. (2016). Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Cell, 164(4), 780–791. doi: 10.1016/j.cell.2016.01.012  Goodman, A. (2018, December 25). Combining a Checkpoint Inhibitor with CAR T-Cell Therapy May Augment Immune Response. Retrieved from https://www.ascopost.com/issues/december-25-2018/combining-a-checkpoint-inhibitor-with-car-t-cell-therapy-may-augment-immune-response/  The Nobel Prize. (2018, October 1). Press release: The Nobel Prize in Physiology or Medicine 2018. Retrieved from https://www.nobelprize.org/prizes/medicine/2018/press-release/
Author: Mr Henry Lau Student Editor, Science Focus The Hong Kong University of Science and Technology